Thus, after confirming ATRA ability to enhance CD38 cell-surface levels (Figure 2A and Figure S4), we tested the anti-MM activity of NAD+-lowering agents alone or in combination with this agent. This evidence concerns the gene CD38 and Miyoshi myopathy.